Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company at the forefront of developing innovative bi-functional fusion proteins. These unique proteins represent a new class of biologic medicine aimed at treating patients with cancer and autoimmune diseases. Shattuck's proprietary Agonist Redirected Checkpoint (ARC®) platform is designed to inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic, a groundbreaking approach in the biotechnology field.
The company's lead product candidate, SL-172154 (SIRPα-Fc-CD40L), is engineered to block the CD47 immune checkpoint and activate the CD40 pathway simultaneously. Currently, SL-172154 is in multiple Phase 1 clinical trials targeting various cancers, including platinum-resistant ovarian cancer and acute myeloid leukemia (AML). Another promising candidate, SL-279252 (PD1-Fc-OX40L), is being developed in collaboration with Takeda Pharmaceuticals and is also in Phase 1 trials.
Shattuck Labs recently embarked on an exciting collaboration with Ono Pharmaceutical to develop bifunctional fusion proteins for autoimmune and inflammatory diseases. This partnership includes a significant financial package with potential milestone payments and royalties, reinforcing Shattuck's strong financial condition and innovative capabilities. Additionally, the company's proprietary gamma delta T cell engager platform, GADLEN™, promises to bridge gamma delta T cells to tumor antigens, offering new hope for cancer treatment.
Recent achievements include rapid enrollment in clinical trials and the FDA's orphan drug designation for SL-172154, highlighting the urgent need for new AML treatments. Shattuck is also actively participating in several high-profile conferences, sharing their latest research and clinical progress. The company is headquartered in Austin, Texas, and Durham, North Carolina, and continues to leverage its scientific expertise to address unmet medical needs.
- Core Business: Development of bi-functional fusion proteins for cancer and autoimmune diseases.
- Recent Achievements: FDA orphan drug designation for SL-172154, collaboration with Ono Pharmaceutical.
- Current Projects: Phase 1 trials for SL-172154 and SL-279252, development of GADLEN™ platform.
- Financial Condition: Strong financial backing with potential milestone payments from partnerships.
- Partnerships: Collaborations with Ono Pharmaceutical and Takeda Pharmaceuticals.
Shattuck Labs (NASDAQ: STTK) reported its Q4 and full-year 2020 financial results, revealing a cash position of $335.4 million as of December 31, compared to $39.1 million in 2019. R&D expenses rose to $9.8 million for Q4 2020, while G&A expenses increased to $3.6 million. The net loss for Q4 was $12.0 million, or $0.31 per share, versus $7.4 million, or $0.97 per share in the prior year. Shattuck anticipates Phase 1 trial data for its lead CD47 checkpoint inhibitor SL-172154 and PD-1 inhibitor SL-279252 in H2 2021, while projecting sufficient cash to fund operations through 2024.
Shattuck Labs, a clinical-stage biotechnology company, announced that two posters will be presented at the AACR Annual Meeting from April 10-15, 2021. The first poster focuses on preclinical data from its GADLEN™ platform, while the second discusses an in vivo model of checkpoint acquired resistance and the therapeutic potential of SL-9258 (TIGIT-Fc-LIGHT). Presenters include Dr. Suresh de Silva and Dr. George Fromm. The abstracts are numbered 1736 and 1697, respectively. Additional details will be available on the AACR website and Shattuck's Events & Presentations section post-event.
Shattuck Labs, Inc. (NASDAQ: STTK) announced its participation in two upcoming investor conferences. CEO Taylor Schreiber will speak at the Cowen 41st Annual Health Care Conference on March 2, 2021, and VP Andrew Neill will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021. Shattuck is focused on developing bi-functional fusion proteins for cancer and autoimmune disease treatment, with its lead program SL-172154 currently in a Phase 1 trial. The company also collaborates with Takeda Pharmaceuticals on another candidate, SL-279252.
Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), announced its participation in Citi's 2021 Virtual Immuno-Oncology Day Conference on February 17-18, 2021. CEO Taylor Schreiber and VP of Finance Andrew Neill will present on the company's innovative bi-functional fusion proteins designed to treat cancer and autoimmune diseases. Shattuck's lead program, SL-172154, is currently undergoing a Phase 1 trial targeting the CD47 checkpoint, while a second program, SL-279252, is in collaboration with Takeda Pharmaceuticals.
Shattuck Labs, a clinical-stage biotechnology company listed on NASDAQ under the symbol STTK, announced its participation in the H.C. Wainwright BioConnect 2021 Conference, set for January 11-14, 2021. The presentation will be led by Andrew Neill, Vice President of Finance and Corporate Strategy, on January 11 at 6:00 a.m. EST. Attendees can access the session via a dedicated webcast link. Shattuck specializes in developing bi-functional fusion proteins for cancer and autoimmune disease treatments.
Shattuck Labs, a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, will present at the 39th Annual J.P. Morgan Healthcare Conference from January 11-14, 2021. CEO Taylor Schreiber will speak on January 14 at 5:20 p.m. EST. The presentation can be accessed live via webcast, with a replay available for 30 days. Shattuck's lead program is SL-172154, currently in Phase 1 trials, aiming to block the CD47 immune checkpoint while activating the CD40 pathway.
Shattuck Labs, a clinical-stage biotechnology firm, announced its inclusion in the Russell 2000® and 3000® Indexes effective December 21, 2020. This milestone is seen as a reflection of investor confidence and is expected to enhance the company's visibility in the investment community, expanding its institutional shareholder base. The Russell indexes, managed by FTSE Russell, are pivotal for asset managers, with about $9 trillion in assets benchmarked against them. Shattuck specializes in bi-functional fusion proteins targeting cancer and autoimmune diseases, including ongoing Phase 1 trials for lead programs.
Shattuck Labs, a clinical-stage biotechnology company focused on developing bi-functional fusion proteins, announced participation in the Evercore ISI 3rd Annual HealthCONx conference taking place December 1-3, 2020. The company's CEO, Taylor Schreiber, and VP of Finance, Andrew Neill, will participate in a fireside chat on December 2 at 1:00 p.m. EST. The event can be accessed via a live webcast, with a replay available for 90 days post-event. Shattuck's lead programs include SL-172154 and SL-279252, both undergoing Phase 1 trials for cancer treatment.
Shattuck Labs (NASDAQ: STTK) announced the initiation of a Phase 1 clinical trial for its CD47 checkpoint inhibitor, SL-172154, targeting ovarian cancer. The company raised approximately $232.3 million in its October 2020 IPO, extending its cash runway into 2024. Financial results for Q3 2020 show a net loss of $11.8 million, increasing from $7.3 million in Q3 2019. R&D expenses rose to $11.8 million, up from $7.9 million in the same period last year. Shattuck remains focused on advancing its clinical trials and maintaining its pipeline through ongoing funding.
Shattuck Labs, a clinical-stage biotechnology firm (NASDAQ: STTK), announced the presentation of preclinical data from its GADLEN™ platform at the SITC Annual Meeting on November 11, 2020. The research showcases the potential of a butyrophilin heterodimer to activate gamma delta T cells, targeting lymphoma cells with the CD19 antigen. CEO Taylor Schreiber emphasized the promise of enhancing gamma delta T cell effectiveness for treating resistant cancers. This milestone represents significant progress in developing GADLEN compounds for various tumor targets.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
What is Shattuck Labs, Inc.'s core business?
What are the main product candidates of Shattuck Labs?
What is the ARC® platform?
Who are Shattuck Labs' key partners?
Where is Shattuck Labs headquartered?
What is SL-172154?
What recent achievements has Shattuck Labs made?
What is the GADLEN™ platform?
What financial condition is Shattuck Labs in?
What are some upcoming events for Shattuck Labs?
